DDInter1927 DDInter1676
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Venlafaxine {u} (Compound) resembles {v} (Compound) Tramadol
Venlafaxine {u} (Compound) resembles {v} (Compound) Desvenlafaxine
Venlafaxine {u} (Compound) binds {v} (Gene) NPY1R
Venlafaxine {u} (Compound) palliates {v} (Disease) panic disorder
Venlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Venlafaxine {u} (Compound) causes {v} (Side Effect) Yawning
Venlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Venlafaxine {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Venlafaxine (Compound) resembles Tramadol (Compound)
Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Venlafaxine (Compound) binds NPY1R (Gene)
Venlafaxine (Compound) palliates panic disorder (Disease)
Venlafaxine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Venlafaxine (Compound) causes Yawning (Side Effect)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine